top of page

Houston Oncology Summit: MD Anderson’s Funda Meric-Bernstam on antibody-drug conjugates

  • blonca9
  • Sep 21, 2023
  • 1 min read

She describes how antibody-drug conjugates have improved over recent years and lists some of her favorite targets and indications that ADCs are going after.



Brought to you by:


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTVHQ

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Allucent logo_tagline.png

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page